Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managin...

書誌詳細
主要な著者:	Giorgio Walter Canonica, Francesco Blasi, Pierluigi Paggiaro, Gianenrico Senna, Giovanni Passalacqua, Antonio Spanevello, Stefano Aliberti, Diego Bagnasco, Marco Bonavia, Matteo Bonini, Luisa Brussino, Caterina Bucca, Maria F. Caiaffa, Cecilia Calabrese, Gianna Camiciottoli, Marco Caminati, Giovanna E. Carpagnano, Cristiano Caruso, Stefano Centanni, Maria E. Conte, Angelo G. Corsico, Lorenzo Cosmi, Maria T. Costantino, Nunzio Crimi, Simona D’Alò, Maria D'Amato, Stefano Del Giacco, Alessandro Farsi, Elisabetta Favero, Maria P. Foschino Barbaro, Gabriella Guarnieri, Giuseppe Guida, Manuela Latorre, Salvatore Lo Cicero, Carlo Lombardi, Luigi Macchia, Francesco Mazza, Francesco Menzella, Manlio Milanese, Marcello Montagni, Paolo Montuschi, Eleonora Nucera, Roberta Parente, Vincenzo Patella, Girolamo Pelaia, Laura Pini, Francesca Puggioni, Luisa Ricciardi, Fabio L.M. Ricciardolo, Luca Richeldi, Erminia Ridolo, Giovanni Rolla, Pierachille Santus, Nicola Scichilone, Giuseppe Spadaro, Andrea Vianello, Vittorio Viviano, Mona R. Yacoub, Maria C. Zappa, Enrico Heffler
フォーマット:	論文
言語:	English
出版事項:	Elsevier 2020-10-01
シリーズ:	World Allergy Organization Journal
主題:	Severe asthma Biologics Oral corticosteroids Real-life Registr
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S1939455120303677

類似資料

Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey
著者:: Claudia Crimi, 等
出版事項: (2023-11-01)

Nasal polyps impact in severe asthma patients: evidences from the SANI
著者:: Giorgio Walter Canonica, 等
出版事項: (2020-08-01)

Economic impact of a more extensive use of FENO testing on the Italian population with asthma
著者:: Carla Rognoni, 等
出版事項: (2023-06-01)

Asthma severity: the patient’s point of view
著者:: Gabriella Guarnieri, 等
出版事項: (2024-12-01)

Is Bronchiectasis (BE) Properly Investigated in Patients with Severe Asthma? A Real-Life Report from Eight Italian Centers
著者:: Giovanna Elisiana Carpagnano, 等
出版事項: (2023-10-01)

Clinical-economic impact of mepolizumab in patients with severe hypereosinophilic asthma
著者:: Diego Bagnasco, 等
出版事項: (2020-08-01)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life
著者:: Diego Bagnasco, 等
出版事項: (2021-02-01)

Severe asthma: One disease and multiple definitions
著者:: Diego Bagnasco, MD, PhD, 等
出版事項: (2021-11-01)

Critical evaluation of asthma biomarkers in clinical practice
著者:: Giuseppe Guida, 等
出版事項: (2022-10-01)

Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center
著者:: Paolo Solidoro, 等
出版事項: (2022-01-01)

Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort
著者:: Marco Caminati, MD, 等
出版事項: (2024-08-01)

Phenotype overlap in the natural history of asthma
著者:: Fabio L.M. Ricciardolo, 等
出版事項: (2023-05-01)

Minimal clinically important difference for asthma endpoints: an expert consensus report
著者:: Matteo Bonini, 等
出版事項: (2020-06-01)

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders
著者:: Diego Bagnasco, 等
出版事項: (2023-08-01)

Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies
著者:: Giorgio Walter Canonica, 等
出版事項: (2021-09-01)

Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: Evidence from the Severe Asthma Network in Italy (SANI)
著者:: Giorgio Walter Canonica, MD, 等
出版事項: (2025-01-01)

Tezepelumab: patient selection and place in therapy in severe asthma
著者:: Francesco Menzella, 等
出版事項: (2024-04-01)

Treatment strategies for asthma: reshaping the concept of asthma management
著者:: Alberto Papi, 等
出版事項: (2020-08-01)

Omalizumab as add‐on therapy in a patient with severe asthma and OSA
著者:: Giulia Scioscia, 等
出版事項: (2020-03-01)

Efficacy of Mepolizumab in patients with previous Omalizumab treatment failure: real life observation
著者:: Diego Bagnasco, 等
出版事項: (2020-08-01)

The evidence on tiotropium bromide in asthma: from the rationale to the bedside
著者:: Dejan Radovanovic, 等
出版事項: (2017-05-01)

Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
著者:: Corrado Pelaia, 等
出版事項: (2023-03-01)

Vascular remodeling and TSLP/angiogenin overexpression in severe mixed asthma
著者:: Francesca Bertolini, 等
出版事項: (2025-02-01)

Erratum to: The evidence on tiotropium bromide in asthma: from the rationale to the bedside
著者:: Dejan Radovanovic, 等
出版事項: (2017-06-01)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
著者:: Erminia Ridolo, 等
出版事項: (2020-10-01)

Brittle asthma
著者:: O. Toungoussova, 等
出版事項: (2016-02-01)

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
著者:: Alessandra Vultaggio, 等
出版事項: (2023-05-01)

Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma–COPD overlap syndrome phenotype
著者:: Lacedonia D, 等
出版事項: (2017-06-01)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
著者:: Giovanna Elisiana Carpagnano, 等
出版事項: (2021-03-01)

SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma
著者:: G. Senna, 等
出版事項: (2017-04-01)

Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis
著者:: Maria D'Amato, 等
出版事項: (2022-05-01)

Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study
著者:: Paolo Solidoro, 等
出版事項: (2019-04-01)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
著者:: Francesco Menzella, 等
出版事項: (2016-12-01)

Positioning tezepelumab for patients with severe asthma: from evidence to unmet needs
著者:: Carlo Lombardi, 等
出版事項: (2024-11-01)

The extracellular matrix of the lung and airway responsiveness in asthma
著者:: F.G. Salerno, 等
出版事項: (2016-01-01)

Alexithymia and asthma: a systematic review
著者:: Orlando Silvestro, 等
出版事項: (2023-08-01)

Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series
著者:: Carlo Lombardi, 等
出版事項: (2024-07-01)

“Characteristics of patients admitted to emergency department for asthma attack: a real-LIFE study”
著者:: Laura Losappio, 等
出版事項: (2019-06-01)

Interleukin-5 in the Pathophysiology of Severe Asthma
著者:: Corrado Pelaia, 等
出版事項: (2019-12-01)

Role of Leukotrienes and Leukotriene Modifiers in Asthma
著者:: Paolo Montuschi
出版事項: (2010-06-01)